Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 3/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22414514 | 0.93 | PARP15 (0.53) | PARP15PARP10PARP2GPR88TDP1 | |
| SCHEMBL13439690 | 0.91 | FFAR1 (0.56) | PARP15PARP10PARP2GPR88TDP1 | |
| SCHEMBL10223303 | 0.88 | TDP1 (0.67) | TDP1KDM1A | |
| SCHEMBL18559634 | 0.87 | MEN1 (0.50) | KMT2AMEN1 | |
| SCHEMBL7601081 | 0.85 | PARP15 (0.51) | PARP15PARP10PARP2GPR88TDP1 | |
| SCHEMBL30932889 | 0.85 | PARP15 (0.51) | PARP15PARP10PARP2GPR88TDP1 | |
| SCHEMBL17246825 | 0.85 | PARP15 (0.51) | PARP15PARP10PARP2GPR88TDP1 | |
| SCHEMBL19876587 | 0.85 | PARP15 (0.51) | PARP15PARP10PARP2GPR88TDP1 | |
| SCHEMBL29024848 | 0.83 | PARP15 (0.64) | PARP15PARP10PARP2TDP1 | |
| SCHEMBL14159031 | 0.83 | HRH3 (0.51) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780819-B2 | Aromatic substituted alkane-core monomers and polymers thereof for volume Bragg gratings | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230008433-A1 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2016161286-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161269-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161279-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
| US-9433501-B2 | Inflation media for implants | DIRECT FLOW MEDICAL, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-25 | — | — | US | disclosed |
| US-8916565-B2 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-23 | — | — | US | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20120022629-A1 | INFLATION MEDIA FOR IMPLANTS | DIRECT FLOW MEDICAL, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | PARP15 1024/4885PARP10 1727/4885PARP2 1847/4885 |
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | PARP15 524/4885PARP10 734/4885PARP2 1348/4885 |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | PARP15 2127/4885PARP10 3087/4885PARP2 4160/4885 |
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | PARP15 319/4885PARP10 1007/4885PARP2 635/4885 |
| US-20230008433-A1 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | PARP15 503/4885PARP10 478/4885PARP2 732/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | PARP15 958/4885PARP10 1406/4885PARP2 965/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | PARP15 1024/4885PARP10 1727/4885PARP2 1847/4885 |
| US-11780819-B2 | Aromatic substituted alkane-core monomers and polymers thereof for volume Bragg gratings | SMAD2, ALK, SMAD3 | PARP15 2457/4885PARP10 2163/4885PARP2 603/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | PARP15 958/4885PARP10 1406/4885PARP2 965/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | PARP15 958/4885PARP10 1406/4885PARP2 965/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | PARP15 524/4885PARP10 734/4885PARP2 1348/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | PARP15 958/4885PARP10 1406/4885PARP2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.